Rivaroxaban for the treatment of saphenous vein graft thrombosis

Konstantinos Marmagkiolis; Mehmet Cilingiroglu

doi:10.1016/j.repc.2015.11.024

Rivaroxaban for the treatment of saphenous vein graft thrombosis

Rev Port Cardiol. 2016 Jul-Aug;35(7-8):447.e1-3. doi: 10.1016/j.repc.2015.11.024. Epub 2016 Jul 8.

[Article in English, Portuguese]

Authors

Konstantinos Marmagkiolis¹, Mehmet Cilingiroglu²

Affiliations

¹ Citizens Memorial Hospital, Heart and Vascular Institute, Bolivar, MO, USA.
² Arkansas Heart Hospital/University of Arkansas for Medical Sciences, Little Rock, AR, USA; Koc University, School of Medicine, Istanbul, Turkey. Electronic address: cilingiroglumehmet@gmail.com.

PMID: 27402444
DOI: 10.1016/j.repc.2015.11.024

Abstract

Thrombus formafigtion plays a significant role in disease of saphenous vein bypass grafts. Use of oral anticoagulants has not been tested in treatment of thrombotic occlusion of saphenous vein graft (SVG) disease. Here we describe the use of the novel oral anticoagulant rivaroxaban in the treatment of occlusive SVG disease with intraluminal thrombus, leading to successful recanalization.

Keywords: Anticoagulant; Anticoagulantes; Doença do enxerto da veia safena; Saphenous vein graft disease; Thrombus; Trombose.

Publication types

Case Reports

MeSH terms

Aged
Coronary Angiography
Coronary Artery Bypass
Factor Xa Inhibitors / therapeutic use*
Female
Graft Occlusion, Vascular / diagnostic imaging
Graft Occlusion, Vascular / drug therapy*
Humans
Rivaroxaban / therapeutic use*
Saphenous Vein* / diagnostic imaging
Venous Thrombosis / diagnostic imaging
Venous Thrombosis / drug therapy*

Substances

Factor Xa Inhibitors
Rivaroxaban